What’s Driving Growth in the Irritable Bowel Syndrome (IBS) Treatment Market? Insights into Key Trends and Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the irritable bowel syndrome (ibs) treatment market?
The market size for treatment of Irritable Bowel Syndrome (IBS) has experienced swift expansion of late. It is projected to increase from $2.79 billion in 2024 to around $3.07 billion in 2025, growing at a compound annual growth rate (CAGR) of 10.2%. Several factors have driven the growth in the past, including a rise in the incidence of IBS, greater awareness among patients, impacts of stress and lifestyle, the presence of patient support and advocacy groups, as well as favourable healthcare reimbursement policies.
What will be the irritable bowel syndrome (ibs) treatment market size in the future?
Rapid expansion is anticipated in the irritable bowel syndrome (IBS) treatment market in the coming years, with its size projected to reach $4.93 billion by 2029, growing at a compound annual growth rate (CAGR) of 12.5%. This surge in the forecasted span can be credited to different factors, including patient-focused healthcare methods, microbial treatments, integration of blockchain in healthcare, patient-reported outcomes (pros), swift regulatory programs, and health data interchangeability. Future trends encompass the incorporation of digital health strategies, advancement in diagnostic technology, escalation in research and development funding, collaboration and partnerships, and the advent of non-pharmacological therapies.
Get your irritable bowel syndrome (ibs) treatment market report here!
What main drivers are fueling expansion in the irritable bowel syndrome (ibs) treatment market?
The increase in irritable bowel syndrome (IBS) cases is anticipated to boost the expansion of the IBS treatment market in the future. IBS is a persistent gastrointestinal ailment that impacts the large intestine (colon) and this surge in its prevalence is attributed to unhealthy lifestyles, poor eating patterns, pollution exposure, and heightened stress levels. Treatment for IBS seeks to diminish the intensity and regularity of IBS symptoms, enhance life quality, and allow patients to better control their conditions. For example, the International Foundation for Gastrointestinal Disorders (IFFGD), a non-profit education and research organization based in the US, has noted that approximately 5-10% of the world’s population had IBS in 2023 and that 25 to 45 million individuals in the United States are affected with IBS. Consequently, the upswing in irritable bowel syndrome (IBS) prevalence is fueling the growth of the IBS treatment market.
What key areas define the segmentation of the global irritable bowel syndrome (ibs) treatment market?
The irritable bowel syndrome (IBS) treatment market covered in this report is segmented –
1) By Drug Type: Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Other Drugs
2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Users: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Lubiprostone: Chronic Idiopathic Constipation Treatment, Irritable Bowel Syndrome with Constipation (IBS-C) Treatment
2) By Linaclotide: IBS-C Treatment, Chronic Idiopathic Constipation Treatment
3) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment
4) By Rifaximin: IBS-D Treatment, Small Intestinal Bacterial Overgrowth (SIBO) Treatment
5) By Alosetron: Severe IBS-D Treatment for Women
6) By Other Drugs: Prucalopride, Tenapanor, Plecanatide
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp
Who are the dominant players expanding their reach in the irritable bowel syndrome (ibs) treatment market?
Major companies operating in the irritable bowel syndrome (IBS) treatment market include Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Cosmo Technologies Ltd., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc.
How are evolving market trends shaping irritable bowel syndrome (ibs) treatment Strategies?
Innovations in product development have surfaced as an important trend influencing the irritable bowel syndrome (IBS) market. Crucial market competitors in the irritable bowel syndrome (IBS) field are focusing their strategies on producing ground-breaking and superior products to solidify their market stance. Take for instance, in April 2022, Ardelyx, a biotech firm based in the US, introduced IBSRELA, a pioneering treatment for IBS-C in adults. It stands as the only NHE3 inhibitor accessible for treating adult irritable bowel syndrome with constipation (IBS-C). IBSRELA, the initial medication from Ardelyx to gain FDA approval, is the first fresh mechanism therapy for IBS-C (irritable bowel syndrome-constipation) to be formulated in nearly a decade. It provides a significant new therapeutic option for constipation, bloating, and abdominal pain- symptoms associated with this debilitating condition.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11978
Which regions are emerging as leaders in the irritable bowel syndrome (ibs) treatment market?
North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (IBS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Aerospace Interior Adhesive Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/aerospace-interior-adhesive-global-market-report
Aerospace Plastics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/aerospace-plastics-global-market-report
Aerospace Coatings Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/aerospace-coatings-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
